Your browser is no longer supported. Please, upgrade your browser.
Settings
GLYC GlycoMimetics, Inc. daily Stock Chart
GLYC [NASD]
GlycoMimetics, Inc.
Index- P/E- EPS (ttm)-1.19 Insider Own0.10% Shs Outstand43.58M Perf Week-10.68%
Market Cap180.43M Forward P/E- EPS next Y-1.36 Insider Trans77.19% Shs Float42.61M Perf Month3.42%
Income-51.50M PEG- EPS next Q-0.34 Inst Own93.40% Short Float5.82% Perf Quarter50.00%
Sales9.00M P/S20.05 EPS this Y-13.80% Inst Trans0.60% Short Ratio3.09 Perf Half Y-11.88%
Book/sh3.41 P/B1.15 EPS next Y-18.00% ROA-32.90% Target Price- Perf Year40.36%
Cash/sh3.37 P/C1.17 EPS next 5Y- ROE-35.70% 52W Range1.82 - 6.72 Perf YTD-25.71%
Dividend- P/FCF- EPS past 5Y-17.30% ROI- 52W High-42.41% Beta2.54
Dividend %- Quick Ratio14.80 Sales past 5Y- Gross Margin- 52W Low112.64% ATR0.33
Employees57 Current Ratio14.80 Sales Q/Q- Oper. Margin- RSI (14)43.82 Volatility7.30% 8.04%
OptionableYes Debt/Eq0.00 EPS Q/Q46.10% Profit Margin- Rel Volume0.28 Prev Close3.93
ShortableYes LT Debt/Eq0.00 EarningsJul 31 AMC Payout- Avg Volume802.53K Price3.87
Recom2.00 SMA20-10.37% SMA507.08% SMA200-3.97% Volume197,297 Change-1.53%
Nov-14-19Initiated ROTH Capital Buy $12
Aug-05-19Downgrade SunTrust Buy → Hold $23 → $5
Aug-05-19Downgrade Piper Jaffray Overweight → Neutral $20 → $6
Aug-05-19Downgrade Jefferies Buy → Hold
Apr-12-19Initiated Piper Jaffray Overweight $20
Dec-18-18Initiated H.C. Wainwright Buy $24
Jul-26-16Initiated SunTrust Buy
Mar-17-15Reiterated Stifel Buy $13 → $14
Jul-31-20 06:30PM  
08:00AM  
Jul-24-20 09:15AM  
Jul-22-20 10:45AM  
Jul-10-20 09:00AM  
Jun-30-20 06:30PM  
08:48AM  
Jun-12-20 12:23PM  
08:41AM  
May-29-20 09:00AM  
May-15-20 12:30PM  
May-12-20 03:48AM  
May-08-20 08:30AM  
May-05-20 07:18AM  
May-01-20 09:01PM  
07:00AM  
Apr-30-20 09:00AM  
Apr-24-20 09:00AM  
Apr-07-20 09:15AM  
Apr-06-20 04:15PM  
Mar-26-20 01:51AM  
Mar-11-20 07:36AM  
Feb-28-20 08:07AM  
Feb-25-20 09:00AM  
Feb-11-20 07:23AM  
Feb-06-20 10:40AM  
Feb-04-20 09:53AM  
Jan-30-20 09:00AM  
Jan-06-20 05:14PM  
03:02PM  
09:00AM  
Dec-19-19 11:09AM  
Nov-29-19 09:41AM  
Nov-15-19 08:29PM  
Nov-13-19 09:00AM  
Nov-08-19 08:00AM  
Nov-07-19 08:24AM  
Nov-06-19 10:03AM  
Oct-31-19 04:15PM  
Oct-30-19 05:23PM  
Sep-19-19 01:08PM  
Aug-27-19 01:59AM  
Aug-18-19 06:25PM  
Aug-08-19 09:00AM  
Aug-05-19 12:21PM  
08:56AM  
06:34AM  
Aug-02-19 08:43PM  
07:24AM  
Jul-25-19 09:00AM  
Jul-23-19 10:23AM  
May-29-19 04:00PM  
May-20-19 05:15PM  
May-11-19 01:27PM  
May-06-19 09:00AM  
May-04-19 04:23PM  
May-02-19 08:27AM  
07:00AM  
06:30AM  
Apr-29-19 04:00PM  
Apr-25-19 04:00PM  
Apr-23-19 09:15AM  
Apr-22-19 09:00AM  
Apr-21-19 01:37AM  
Apr-12-19 09:00AM  
Apr-04-19 04:00PM  
Mar-07-19 05:30PM  
Mar-06-19 02:46PM  
12:56PM  
07:30AM  
06:30AM  
Mar-05-19 04:30PM  
Feb-27-19 04:30PM  
Feb-11-19 08:15AM  
Dec-12-18 10:46AM  
Dec-04-18 07:00AM  
Dec-03-18 07:00AM  
Nov-29-18 09:15AM  
Nov-28-18 09:00AM  
Nov-27-18 07:15AM  
Nov-19-18 09:00AM  
Nov-16-18 03:27AM  
Nov-06-18 07:40AM  
Nov-02-18 07:39AM  
07:30AM  
Nov-01-18 09:58AM  
Oct-26-18 09:00AM  
Oct-24-18 09:00AM  
Oct-10-18 04:54PM  
Aug-31-18 07:45AM  
Aug-29-18 04:00AM  
Aug-14-18 09:00AM  
Aug-10-18 10:15PM  
03:17PM  
06:30AM  
Aug-09-18 04:49PM  
04:05PM  
Aug-02-18 09:00AM  
Jul-27-18 07:50AM  
Jul-18-18 07:20AM  
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and is in a Phase III clinical trial, conducted by its strategic collaboration with Pfizer Inc. It is also developing uproleselan, an E-selectin antagonist that is evaluated in a Phase I/II clinical trial as a potential treatment for acute myeloid leukemia (AML), as well as Phase III trial to treat relapsed/refractory AML. In addition, the company offers GMI-1359 that has completed Phase I clinical trial to target E-selectin and a chemokine receptor for various tumor types. Further, it is developing various other programs, including GMI-1687, an antagonist of E-selectin; and Galectin-3, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
JUNIUS DANIEL MDirectorMar 09Buy3.4020,00068,00038,000Mar 10 06:12 PM
Magnani John L.SVP of Research, CSOJan 06Option Exercise1.12106,983119,821289,760Jan 06 06:23 PM
Magnani John L.SVP of Research, CSODec 20Option Exercise1.12106,984119,822182,777Dec 23 04:13 PM
BVF PARTNERS L P/IL10% OwnerSep 05Buy3.181,668,7465,309,9503,639,935Sep 09 04:49 PM
JUNIUS DANIEL MDirectorAug 13Buy3.1810,00031,80018,000Aug 15 04:03 PM
King Rachel K.President, CEOAug 06Option Exercise1.12166,759186,770307,144Aug 07 04:29 PM